$1.51 Million in Sales Expected for Senseonics Holdings Inc (SENS) This Quarter

Wall Street analysts expect Senseonics Holdings Inc (NASDAQ:SENS) to post $1.51 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Senseonics Holdings’ earnings, with the highest sales estimate coming in at $1.52 million and the lowest estimate coming in at $1.51 million. Senseonics Holdings posted sales of $40,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 3,675%. The firm is expected to announce its next earnings report on Thursday, November 2nd.

On average, analysts expect that Senseonics Holdings will report full year sales of $1.51 million for the current year, with estimates ranging from $5.60 million to $6.15 million. For the next financial year, analysts expect that the company will report sales of $33.46 million per share, with estimates ranging from $27.00 million to $39.91 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Senseonics Holdings.

Senseonics Holdings (NASDAQ:SENS) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.01. The business had revenue of $0.81 million for the quarter, compared to analyst estimates of $0.81 million.

A number of brokerages have recently commented on SENS. Zacks Investment Research raised shares of Senseonics Holdings from a “sell” rating to a “hold” rating in a research report on Tuesday, August 15th. BTIG Research reissued a “buy” rating and issued a $4.50 price objective on shares of Senseonics Holdings in a research report on Sunday, May 28th.

In other news, COO Mukul Jain sold 13,115 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $3.25, for a total value of $42,623.75. Following the sale, the chief operating officer now owns 13,115 shares of the company’s stock, valued at $42,623.75. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

A number of hedge funds and other institutional investors have recently bought and sold shares of SENS. Raymond James Financial Services Advisors Inc. bought a new stake in Senseonics Holdings during the first quarter worth $147,000. Renaissance Technologies LLC bought a new stake in Senseonics Holdings during the first quarter worth $111,000. HarbourVest Partners LLC bought a new stake in Senseonics Holdings during the first quarter worth $470,000. Blackstone Group L.P. bought a new stake in Senseonics Holdings during the first quarter worth $614,000. Finally, ING Groep NV raised its position in Senseonics Holdings by 87.7% during the second quarter. ING Groep NV now owns 225,833 shares of the company’s stock worth $406,000 after acquiring an additional 105,494 shares in the last quarter.

Senseonics Holdings (NASDAQ SENS) opened at 3.19 on Friday. Senseonics Holdings has a 52 week low of $2.15 and a 52 week high of $4.05. The firm’s market cap is $393.01 million. The stock’s 50 day moving average is $3.09 and its 200 day moving average is $2.74.

ILLEGAL ACTIVITY WARNING: “$1.51 Million in Sales Expected for Senseonics Holdings Inc (SENS) This Quarter” was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://transcriptdaily.com/2017/09/17/1-51-million-in-sales-expected-for-senseonics-holdings-inc-sens-this-quarter.html.

About Senseonics Holdings

Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.

Get a free copy of the Zacks research report on Senseonics Holdings (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senseonics Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply